Cancer screening does not begin and end with a test. New tests enter an established screening landscape, and companies introducing them have a responsibility to help patients, care teams, and health systems understand how each option fits alongside recommended screening, what the test can and cannot do, and the steps to follow after care teams and patients receive results.
Freenome’s approach to blood-based cancer screening is Personalized Cancer Detection. It brings together screening based on patients’ risks with blood-based tests tailored to specific cancer indications. The goal is to complement guideline-recommended methods and help expand screening participation. Personalized Cancer Detection is delivered through the SimpleScreenTM portfolio. With SimpleScreen Lung now launched and SimpleScreen CRC available as an add-on for eligible patients, this approach is moving into clinical practice.
The success of screening programs also depends on how screening is delivered and supported. Freenome Digital Health can help health systems use EHR-native capabilities to identify eligible patients, engage patients and care teams, and integrate screening into routine workflows. Together, blood-based tests and digital support can help create more complete and connected cancer screening programs.
Freenome’s relationships with advocacy groups, including GO2 for Lung Cancer (GO2) and Fight Colorectal Cancer (Fight CRC), bring perspectives from the people and communities screening is meant to serve. These perspectives inform how Freenome thinks about both Personalized Cancer Detection and Freenome Digital Health. Signe Fransen, Freenome’s Vice President of Medical Affairs and Advocacy, said, “Advocacy perspectives keep us focused on access, informed choice, and follow-through—not just whether someone takes a test.”
The groups’ input also speaks to what makes partnerships between laboratories and advocacy organizations meaningful. GO2 says advocates should be strategic partners, bringing patient and community perspectives into research, implementation, and communication. Fight CRC emphasizes the importance of independence and early input, saying, “The most respectful partnerships invite patient input early, while it can still shape decisions.” These perspectives help keep patient understanding, care team conversations, and health system support for screening and follow-up at the center of Freenome’s work.
These principles are reflected in Freenome’s patient education content, including its pre- and post-test educational videos. GO2 describes its engagement with Freenome as focused on “elevating the patient voice in discussions about innovation in lung cancer screening and early detection.” GO2 provided feedback on the lung videos, and Fight CRC on the colorectal cancer videos. Available in English and Spanish, with support for additional languages in development, the video scripts use plain language at about a sixth-grade reading level. They explain why screening matters, describe screening options, and help patients understand potential results and next steps. GO2’s guidance is to present each option in context: “laboratories should ensure that patients receive clear, balanced information about the benefits, limitations, and appropriate role of each screening option.” Advocacy perspectives have also informed Freenome’s approach to clinician resources that help care teams explain results and discuss follow-up with patients.
Advocacy partnerships include work to better understand the screening journey. Fight CRC calls Freenome “a thoughtful partner in our shared goal of expanding screening participation.” They point to Freenome’s data analysis for its Colorectal Cancer Care Initiative and continued collaboration with Fight CRC, researchers, and other partners. That work brings together different areas of expertise to questions of screening analysis, methodology, and data quality. Freenome has also participated in Fight CRC’s annual Call on Congress, joining survivors, caregivers, and advocates to bring important patient and community perspectives to conversations with lawmakers.
For health system and clinical leaders, these relationships offer a view into how Freenome approaches the responsibilities that come with introducing new screening tests and the capabilities that support their use: clarifying each test’s role, supporting informed conversations, and incorporating patient and advocacy perspectives. How a screening option is presented and integrated into care can influence clinician trust and whether a health system views it as aligned with its commitment to evidence-based care.
Our mission is to relentlessly confront lung cancer on every front, every day, for everyone. As the nation’s leading lung cancer advocacy organization that was founded by patients and survivors, we are dedicated to increasing survival and quality of life for those at risk, diagnosed, and living with lung cancer.
Fight CRC Mission
We fight to cure colorectal cancer and serve as relentless champions of hope for all affected by this disease through informed patient support, impactful policy change, and breakthrough research endeavors.
The SimpleScreen™ CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit.
SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
Precaution: Based on data from clinical studies, SimpleScreen CRC has limited detection (57%) of Stage I colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted). One out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a screening colonoscopy.
© 2026 Freenome, LLC. SimpleScreen Lung has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Freenome’s Clinical Laboratory is CAP accredited, and certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. The following are trademarks of Freenome, LLC: FREENOME®, SimpleScreen™, SimpleScreen logo™, and PREEMPT CRC®. All rights reserved.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
